ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment

Christopher D Barrett, Hunter B Moore, Michael B Yaffe, Ernest E Moore, Christopher D Barrett, Hunter B Moore, Michael B Yaffe, Ernest E Moore

No abstract available

Keywords: COVID-19; International Society on Thrombosis and Haemostasis (ISTH); acute respiratory distress syndrome (ARDS); anticoagulation; disseminated intravascular coagulation.

References

    1. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020
    1. Lillicrap D. Disseminated intravascular coagulation in patients with 2019‐nCoV pneumonia. J Thromb Haemost. 2020;18:786–787.
    1. Li T., Lu H., Zhang W. Clinical observation and management of COVID‐19 patients. Emerg Microbes Infect. 2020;9:687–690.
    1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847.
    1. Wang D., Hu B., Hu C., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
    1. Yang X., Yu Y., Xu J., et al. Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med. 2020 doi: 10.1016/S2213-2600(20)30079-5.
    1. Han H., Yang L., Liu R., et al. Prominent changes in blood coagulation of patients with SARS‐CoV‐2 infection. Clin Chem Lab Med. 2020 doi: 10.1515/cclm-2020-0188.
    1. Xu J., Wang L., Zhao L., et al. Risk assessment of venous thromboembolism and bleeding in COVID‐19 patients. Respir Res. 2020 doi: 10.21203/-18340/v1.
    1. Cotton R.C., Shaikh M.S., Dent R.V. Heparin resistance and plasma fibrinogen in elderly subjects with and without occlusive vascular disease. J Atheroscler Res. 1968;8:959–966.
    1. Klovaite J., Nordestgaard B.G., Tybjaerg‐Hansen A., Benn M. Elevated fibrinogen levels are associated with risk of pulmonary embolism, but not with deep venous thrombosis. Am J Respir Crit Care Med. 2013;187:286–293.
    1. van Hylckama Vlieg A., Rosendaal F.R. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost. 2003;1:2677–2678.
    1. Kamphuisen P., Eikenboom J., Vos H., et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999;81:680–683.
    1. Koster T., Rosendaal F.R., Reitsma P.H., et al. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case‐control study of plasma levels and DNA polymorphisms–the Leiden Thrombophilia Study (LETS) Thromb Haemost. 1994;71:719–722.
    1. Harr J.N., Moore E.E., Chin T.L., et al. Postinjury hyperfibrinogenemia compromises efficacy of heparin‐based venous thromboembolism prophylaxis. Shock. 2014;41:33–39.
    1. Livingston E., Bucher K. Coronavirus disease 2019 (COVID‐19) in Italy. JAMA. 2020;323:1335.
    1. Bone R.C., Francis P.B., Pierce A.K. Intravascular coagulation associated with the adult respiratory distress syndrome. Am J Med. 1976;61:585–589.
    1. Ware L.B. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006;27:337–349.
    1. Ware L.B., Matthay M.A. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334–1349.
    1. Luo W, Yu H, Gou J, et al. Clinical pathology of critical patient with novelcoronavirus pneumonia (COVID‐19). Preprints (not peer reviewed); posted 9 March2020.
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(4):844–847.
    1. Hardaway R.M., 3rd, Mc K.D. Disseminated intravascular coagulation: a cause of shock. Ann Surg. 1959;149:462–470.
    1. Hardaway R.M., Brune W.H., Geever E.F., Burns J.W., Mock H.P. Studies on the role of intravascular coagulation in irreversible hemorrhagic shock. Ann Surg. 1962;155:241–250.
    1. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24–33.
    1. Matsuda T., Murakami M. Relationship between fibrinogen and blood viscosity. Thromb Res. 1976;8:25–33.
    1. Danzi G.B., Loffi M., Galeazzi G., Gherbesi E. Acute pulmonary embolism and COVID‐19 pneumonia: a random association? Eur Heart J. 2020 doi: 10.1093/eurheartj/ehaa254.
    1. Naicker S., Yang C.‐.W., Hwang S.‐.J., et al. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824–828.
    1. de Haan C.A., Li Z., te Lintelo E., et al. Murine coronavirus with an extended host range uses heparan sulfate as an entry receptor. J Virol. 2005;79:14451–14456.
    1. Hardaway R.M., Williams C.H., Marvasti M., et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med. 1990;18:1413–1418.
    1. Stringer K.A., Hybertson B.M., Cho O.J., Cohen Z., Repine J.E. Tissue plasminogen activator (tPA) inhibits interleukin‐1 induced acute lung leak. Free Radic Biol Med. 1998;25:184–188.
    1. Liu C., Ma Y., Su Z., et al. Meta‐analysis of preclinical studies of fibrinolytic therapy for acute lung injury. Front Immunol. 2018;9:1898.
    1. Moore H.B., Barrett C.D., Moore E.E., et al. Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID‐19 associated acute respiratory distress syndrome (ARDS)? J Trauma Acute Care Surg. 2020 doi: 10.1097/TA.0000000000002694.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi